Day One Biopharmaceuticals Stock Jumps on Renewed M&A Rumors
Day One Biopharmaceuticals shares surge 26% to $12.62 amid fresh speculation of a potential buyout.
Already have an account? Sign in.
Day One Biopharmaceuticals shares surge 26% to $12.62 amid fresh speculation of a potential buyout.
Deutsche Bank, BofA & Benchmark raise Unity to Buy with $50 targets after blowout Q2 results and sustainable Vector growth.
Investors sent Doximity’s stock to the moon after a clean Q1 revenue beat, higher guidance, and clear signs of AI product-market fit.
DraftKings Q2 revenue fell 5% to $1.44B, missing estimates, as winning bets and promotions weighed on results. Guidance held; handle up 15%.